| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 538,407 | |||
| Prepayments and other receivables | 28,074 | |||
| Marketable securities, current | 164,539 | |||
| Restricted cash | 1,308 | |||
| Total current assets | 732,328 | |||
| Marketable securities, net of current portion | 53,091 | |||
| Property, plant and equipment, net | 323 | |||
| Operating right of use asset | 246 | |||
| Intangible assets | 439 | |||
| Total assets | 786,427 | |||
| Accounts payable | 3,632 | |||
| Accrued expenses and other current liabilities | 10,098 | |||
| Lease liability, current | 181 | |||
| Derivative warrant liabilities | 44,361 | |||
| Total current liabilities | 58,272 | |||
| Lease liability, net of current portion | 85 | |||
| Total liabilities | 58,357 | |||
| Ordinary shares | 14,107 | |||
| Additional paid-in capital | 1,396,790 | |||
| Accumulated loss | -687,467 | |||
| Accumulated other comprehensive income | 4,640 | |||
| Total shareholders' equity | 728,070 | |||
| Total liabilities and shareholders' equity | 786,427 | |||
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)